A foundation that was established in 1998 and is based in New York, NY. The foundation is currently funding new investment opportunities in the life science space (specifically Alzheimer’s disease and related dementia) through two grants; the Biotechnology Development Program for existing early stage private companies and the Biotechnology Founders Technology Transfer Program supports the establishment of new companies. The foundation typically provides funding of up to $350,000 per year for up to two years for pre-clinical programs or $1-3 M for clinical stage programs. They will invest with other groups for larger deals. The foundation typically provides investments as equity, a convertible loan, and recoverable grants. The foundation will consider investments globally.

The foundation is currently most interested in companies in the therapeutics space but will consider diagnostics if the technology provides significant benefit for Alzheimer’s patients or will accelerate clinical trials. The foundation is interested in both small molecules and biologics and will providing funding from companies anywhere from High throughput screening to Phase IIa of clinical Trials.

The foundation is looking for companies with experienced management teams. The firm looks to be an active value-added investor to help companies with securing future financing rounds when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm founded in 2002 is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. The firm primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where The firm does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is the firm’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. The firm will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of an Europe-headquartered bank invests in early-stage companies in the life science industry among other technologically oriented industries, and is looking to engage in late seed, Series A or Series B rounds. The initial investments typically range from 0.5M to 3M Euros. The firm is open to both leading and co-investing, and prefer to syndicate with other investors. The firm is primarily interested in companies based in Germany, Austria and Switzerland.

The firm is looking for new opportunities in the life science space including therapeutics, diagnostics, medical devices and digital health. The firm is interested in companies from pre-clinical to clinical stages onward, and would like to see some preclinical validations for therapeutics companies or prototypes for medical devices. The firm is opportunistic in terms of sector, subsectors and indications, and is open to considering orphan diseases.

The firm doesn’t have specific requirements for management teams. The firm is open to both leading and co-investing, and prefers to take a board seat when investing larger amounts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M (USD) of equity capital with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in the US, Europe and China. The firm’s China office can provide companies with the resources they need for successful market entry in Asian markets.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.